Related Experiment Video

Updated: May 11, 2026

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer
07:59

Ultra-Fast Amplicon-Based Next-Generation Sequencing in Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

Molecularly targeted therapies in locally advanced non-small-cell lung cancer

Siddhartha Devarakonda1, Daniel Morgensztern, Ramaswamy Govindan

  • 1Department of Internal Medicine, St. Luke's Hospital, Chesterfield, MO, USA.

Clinical Lung Cancer
|May 21, 2013
PubMed

Insights

Locally advanced non-small cell lung cancer (NSCLC) treatment shows modest outcomes. This review examines targeted therapies and proposes a new trial for molecularly selected NSCLC patients.

Area of Science:

  • Oncology
  • Medical Research
  • Clinical Trials

Background:

  • Non-small cell lung cancer (NSCLC) often presents as locally advanced disease, unsuitable for surgical removal.
  • Current standard treatment, concurrent chemoradiation, yields limited patient outcomes.
  • There has been a lack of significant therapeutic advancement for this patient group over the last decade.

Purpose of the Study:

  • To review existing clinical trials investigating molecular targeted therapies for locally advanced NSCLC.
  • To propose a prospective clinical trial design for evaluating targeted drugs in a molecularly selected NSCLC population.

Main Methods:

  • Literature review of completed clinical trials on targeted therapies in locally advanced NSCLC.
  • Outline of a prospective clinical trial protocol for molecularly targeted drug evaluation.

Main Results:

  • Summary of outcomes from various trials of molecular targeted therapies in NSCLC.
  • Identification of potential targeted agents and patient selection criteria.

Conclusions:

  • Current treatment approaches for locally advanced NSCLC have shown limited efficacy.
  • Targeted therapies in molecularly selected NSCLC patients represent a promising future direction.
  • A prospective clinical trial is proposed to further investigate the efficacy of targeted drugs in this specific NSCLC population.
Keywords:
Concurrent chemoradiationLocally advanced NSCLCNSCLCTargeted therapy

More Related Videos

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing05:17

Detection of Targetable Alterations in Non-small Cell Lung Cancer using Next-generation Sequencing

Published on: October 10, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...